Bicycle Therapeutics Q2 net loss $50.3M ($0.72/share); cash $510.1M; clinical progress on nuzefatide and zelenectide

BICYCLE THERAPEUTICS PLC

Net loss of $50.3M ($0.72 per share) for Q2 2026, compared to $79.0M ($1.14) in Q2 2025.
Cash and equivalents of $510.1M as of June 30, 2026; expected cash runway into 2030.
R&D expenses fell to $41.2M from $71.0M, driven by workforce reduction and lower zelenectide costs.
First patient dosed in Phase 2 trial of nuzefatide in recurrent pancreatic cancer in April 2026.
Expanded Clinical Advisory Board with Thomas Powles, MD, a leader in urothelial cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.